Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition (Q38852158)

7 September 2017

title

Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition (English)

1 reference

7 September 2017

1 reference

Yaobin Liu

1 reference

7 September 2017

Xian He

1 reference

7 September 2017

Yiyan Sui

1 reference

7 September 2017

Rong Yu

1 reference

7 September 2017

Guoqiang Xu

1 reference

7 September 2017

language of work or name

English

0 references

publication date

13 July 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

589

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

2233-2240

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

7 September 2017

1 reference

Current therapeutic strategies for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Current and emerging treatment options for patients with relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta -catenin and promotes GSK-3beta -dependent phosphorylation of beta -catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

β-catenin is a target for the ubiquitin–proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Ikaros, CK2 kinase, and the road to leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Signals from the lysosome: a control centre for cellular clearance and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

The lysosome: from waste bag to potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Cellular and nuclear degradation during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

A Complex of Cdc4p, Skp1p, and Cdc53p/Cullin Catalyzes Ubiquitination of the Phosphorylated CDK Inhibitor Sic1p

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Cytoplasmic tail phosphorylation of the alpha-factor receptor is required for its ubiquitination and internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.06.044

10.1016/J.FEBSLET.2015.06.044

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference